Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
C3	718	GLOBULIN, IMMUNE	CHEMBL1201599	binder	DrugBank	20441428, 17911465, 17351760

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
C3	rs2250656	TT	bevacizumab	efficacy	no	as determined by changes in visual acuity score. Please note; alleles were reported as A and G, here we represent these with the complementary alleles T and C, respectively.	Genotype TT is not associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype CC.	22594510	827920125
C3	rs2230205	TT	bevacizumab	efficacy	no	as determined by changes in visual acuity score. Please note; alleles were reported as A and G, here we represent these with the complementary alleles T and C, respectively.	Genotype TT is not associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype CC.	22594510	827920120
C3	rs2230199	GG	bevacizumab	efficacy	no	No significant difference in genotype frequencies was seen between patients classified as non-responders, and those classified as responders or partial responders. Responder status was determined by optical coherence tomography; please refer to the paper directly for definitions of responder, partial responder, and non-responder.	Genotype GG is not associated with response to bevacizumab in people with Macular Degeneration as compared to genotypes CC + CG.	23584701	1184166141
C3	rs2230199	CC + CG	eculizumab	efficacy	no	Response was defined as no red blood cell transfusion at any time after the first 6 months on eculizumab treatment (patients had a median follow-up of 52 months, range of 11-98 months). In the paper, GG = Slow/Slow.	Genotypes CC + CG is not associated with response to eculizumab in people with paroxysmal nocturnal hemoglobinuria as compared to genotype GG.	24038027	1184512020
C3	rs2230199	GG	bevacizumab	efficacy	no	No significant differences in mean visual acuity (units = letters), mean visual acuity change from baseline (units = letters), >= 15-letter increase from baseline (%), mean number of injections, retinal thickness (%, units = um), mean change in total foveal thickness from baseline (units = um), dry on optical coherence tomography (%), leakage on fluorescein angiography (%) or mean change in lesion size from baseline (units = disc area) after 1 year of treatment were seen between genotypes. p <= 0.01 was considered statistically significant to adjust for multiple comparisons.	Genotype GG is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CG.	23337555	1183491605